利拉鲁肽联合达格列净对超重或肥胖2型糖尿病患者肾功能、氧化应激以及内脏脂肪含量的影响.

Objective: To investigate the effects of liraglutide combined with dapagliflozin on renal function, oxidative stress and visceral fat content in overweight or obese patients with type 2 diabetes (T2DM). Method: our hospital in January 2018 ² 108 cases of overweight or obese patients with T2DM received during May 020, divided into a control group (n = 54) and observation group (n = 54) in accordance with the random number table. The control group was treated with liraglutide, and the observation group was treated with liraglutide combined with dapagliflozin for 12 weeks. Comparing the two groups of renal function [Sera Cystatin C (CysC), Serum Creatinine (Scr), Serum Uric Acid (SUA)], oxidative stress [Malondialdehyde (MDA), Glutathione Peroxidase (GSH- PX), superoxide dismutase (SOD)], body mass index (BMI), waist circumference, blood glucose indicators [fasting blood glucose (FBG), 2 h postprandial blood glucose (2hPBG), glycosylated hemoglobin (HbA1c)] and body composition indicators (Percentage of body fat, content of visceral fat), record the adverse reactions of the two groups during treatment. Results: BMI, waist circumference, 2hPBG, FBG, HbA1c decreased in the two groups after treatment, and the observation group was lower than the control group (P<0.05). MDA decreased in the two groups after treatment, and the observation group was lower than the control group (P<0.05), SOD and GSH-PX increased after treatment in the two groups, and the observation group was higher than the control group (P<0.05). The percentage of body fat and visceral fat content in the two groups decreased after treatment, and the observation group was lower than the control group (P<0.05). There was no significant difference in CysC, Scr, SUA and between groups before and after treatment (P>0.05). There was no statistical difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Liraglutide combined with dapagliflozin on the basis of the treatment of overweight or obese T2DM patients has a definite hypoglycemic effect, reduces the body's oxidative stress, reduces the visceral fat content, has no significant effect on renal function, and does not increase the incidence of adverse reactions . [ABSTRACT FROM AUTHOR]